NCT05321147

Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

A Multi-center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Innate Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.

Detailed description

This is an open-label, single-arm multicenter study. Eligible patients will be enrolled and will receive fixed dose of 750mg Lacutamab as a 1-hour IV infusion.

Conditions

• Peripheral T Cell Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	lacutamab	Patients will receive a fixed dose of 750mg as 1-hour IV infusion

Timeline

• Start date: 2022-03-17
• Primary completion: 2023-11-19
• Completion: 2024-02-08
• First posted: 2022-04-11
• Last updated: 2024-03-28

Locations

20 sites across 2 countries: United States, South Korea

Regulatory

• FDA-regulated drug study